Prothena to Present at the Jefferies Virtual Healthcare Conference on June 3

Rhea-AI Summary

DUBLIN, Ireland, May 27, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) announced its senior management will present at the Jefferies Virtual Healthcare Conference on June 3 at 3:30 PM ET. Investors can access the presentation via the investor relations section of the company's website. A replay will be available for 90 days post-presentation. Prothena focuses on the discovery of therapies for diseases related to protein misfolding, including Alzheimer's and Parkinson's, with a diverse pipeline of partnered and proprietary programs.

DUBLIN, Ireland, May 27, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that members of its senior management team will present and participate in the Jefferies Virtual Healthcare Conference on Wednesday June 3 at 3:30 PM ET.

A webcast of the company presentation can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.

About Prothena

Prothena Corporation plc is a clinical-stage neuroscience company with expertise in protein misfolding, focused on the discovery and development of novel therapies with the potential to fundamentally change the course of devastating diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s partnered programs include prasinezumab (PRX002/RG7935), in collaboration with Roche for the potential treatment of Parkinson’s disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) or other neurodegenerative diseases. Prothena’s proprietary programs include PRX004 for the potential treatment of ATTR amyloidosis, and programs that target Aβ (Amyloid beta) for the potential treatment of Alzheimer’s disease. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Media and Investor Contact:

Ellen Rose, Head of Communications
650-922-2405, ellen.rose@prothena.com

FAQ

When will Prothena present at the Jefferies Virtual Healthcare Conference?

Prothena will present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 3:30 PM ET.

How can I access Prothena's presentation at the Jefferies Conference?

You can access Prothena's presentation through the investor relations section of their website.

What is Prothena's focus in drug development?

Prothena focuses on discovering therapies for diseases related to protein misfolding, including Alzheimer's and Parkinson's disease.

What are some of the diseases Prothena's therapies target?

Prothena's therapies target Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative diseases.

What is the stock symbol for Prothena Corporation?

The stock symbol for Prothena Corporation is PRTA.